



#KCRS20 October 22-23, 2020
kcrs.kidneycan.org

A Focus on Translational Research

Thursday, October 22nd

- 3:00-4:00 p.m. EDT **Registration**
Please visit our sponsor displays!
- 4:00-4:10 p.m. EDT **Welcome, Introductions, & General Information**
- 4:10-4:50 p.m. EDT **Keynote: "Can Studies of the VHL Gene Get Us to Curative Combination Therapies for Kidney Cancer?"**
Dr. William Kaelin, Jr., Nobel Laureate
Dana-Farber Cancer Institute
- 4:50-5:00 p.m. EDT **Keynote: Questions & Discussion**
- 5:00-6:00 p.m. EDT **The Next Frontier: New Molecular Targets for Kidney Cancer***
Moderated by Eric Jonasch, MD Anderson Cancer Center
& Naomi Haas, University of Pennsylvania
- Therapeutic Targeting of Cystine Addiction of RCC
Jen Tsan Chi, Duke University
- TBK1 Serves as a Novel Therapeutic Target in Kidney Cancers with VHL Loss
Qing Zhang, University of Texas Southwestern
- Targeting IGF1R Signaling in MTAP-Deficient Kidney Cancer
Ching-Hsien Chen, University of California Davis
- Studying BAP1 in Regulating Glucose Dependency in Renal Cancer: Mechanisms and Preclinical Translation
Boyi Gan, MD Anderson Cancer Center
- 6:00-6:15 p.m. EDT **Break**
- 6:15-7:30 p.m. EDT **Getting the Right Therapies to the Right Patients: Emerging Biomarkers for Kidney Cancer***
Moderated by Sabina Signoretti, Dana Farber Cancer Institute
& Payal Kapur, University of Texas Southwestern
- Characterizing and Targeting the Microenvironmental Barriers to Immunotherapeutic Response in RCC: Team Research
Ari Hakimi & Tim Chan, Memorial Sloan Kettering Cancer Center
- Endogenous Retrovirus Expression, Chromatin Abnormalities, and Response to Immune Checkpoint Blockade in Clear Cell RCC
Shridar Ganesan, Rutgers Cancer Institute
- Host Immune Signatures as Therapy Response Biomarkers in Metastatic Renal Cell
Ziad Bakouny, Dana Farber Cancer Institute
- Development and Testing of Circulating-Free Methylation DNA as a Prognostic Biomarker for Recurrent Kidney Cancer
Daniel De Carvalho, Princess Margaret Cancer Centre
- Biomarkers of IO in RCC: What Is an Ideal Industry-Academic Relationship?
[Presenter TBD]

**Q & A and Panel Discussion following each topic and at end of session.*



#KCRS20 October 22-23, 2020
kcrs.kidneycan.org

A Focus on Translational Research

Friday, October 23rd

- 7:00-8:00 a.m. EDT **Registration**
Please visit our sponsor displays!
- 8:15-8:30 a.m. EDT **Welcome, Introductions, & General Information**
- 8:30-9:30 a.m. EDT **Best of 2020: Including Updates from ESMO***
Moderated by Toni Choueiri, Dana Farber Cancer Institute
and Brian Rini, Vanderbilt University
- Translational Science Updates from ESMO**
Tom Powles, Barts Cancer Centre
- Important Clinical Updates from ESMO**
Laurence Albiges, Institut Gustave Roussy
- The Ever-Changing Clinical Landscape of Kidney Cancer Therapies: Updates and Ongoing Trials**
Robert Motzer, Memorial Sloan Kettering Cancer Center
- 9:30-10:00 a.m. EDT **Break**
Please visit our sponsor displays!
- 10:00-11:00 a.m. EDT **The Next Generation of Immune Therapies***
Moderated by Hans Hammers, University of Texas Southwestern
& John Haanen, Netherlands Cancer Institute
- Targeted Pro-Inflammatory Prodrugs for the Immunotherapy of Kidney Cancer**
Hans Hammers, University of Texas Southwestern
- Oncolytic Single-Cycle Replicating Immunotherapies for Kidney Cancer**
Michael Barry, Mayo Clinic
- Personalized T-Cell Immunotherapy for Renal Cell Carcinoma**
Shreeran Akilesh, University of Washington
- Lessons in Immunotherapy Failures**
Ira Mellman, Genentech, Cancer Immunology
- 11:00-12:00 p.m. EDT **Lunch Break**
- 12:00-1:30 p.m. EDT **Optional CME Session:**
"The Emerging Role of Biomarkers in mRCC: Selecting Patients and Predicting Response to Treatment"

**Q & A and Panel Discussion following each topic and at end of session.*



#KCRS20 October 22-23, 2020
kcrs.kidneycan.org

A Focus on Translational Research

#KCRS On-Demand: Pre-Recorded Sessions to View at Your Convenience

The Next Frontier: New Molecular Targets for Kidney Cancer

Profilin 1 as a Novel Target in Patients with RCC

Partha Roy, University of Pittsburgh

Functionally Characterizing the Enhancer Cistrome in Advanced Human Kidney Cancer

[Presenter TBD]

Novel Models for Kidney Cancer Research

Unlocking the Human Relevance of a New Genetic Papillary RCC Mouse Model

Richard Link, Baylor College of Medicine

Modeling Spatial Ecology in Clear Cell Renal Cell Carcinoma Model: A Novel Tool to Support Drug Sequencing Decisions

Brandon Manley, H. Lee Moffitt Cancer Center

Kidney Cancer (DFCI) Model

Laura Stransky, Dana Farber Cancer Institute

Kidney Cancer (UTSW) Model

[Presenter TBD]

Evolving Imaging Methods for Improved Diagnosis and Response Prediction

Noninvasive Diagnostic Assessment of Kidney Cancer Using Hyperpolarized ¹³C L-Tryptophan

Lloyd Lumata, University of Texas at Dallas

Immune Checkpoint Targeted Immuno-PET to Identify Therapy-Induced Adaptive Resistance: Research Partnerships

Xiankai Sun, University of Texas Southwestern

Quantitative CT Biomarkers to Predict Metastatic RCC Response to Antiangiogenic Therapy

Andrew Smith, University of Alabama at Birmingham

Germline Genetics and Implications

Biological Determinants of Kidney Cancer Health Disparities

Khadijah Mitchell, Lafayette College

Variant Kidney Cancer Histologies: Characterization and Therapeutic Targeting

Chromophobe RCC: New Concepts in Pathogenesis

Elizabeth Henske, Brigham & Women's Hospital

Defining the Role of Beta-Catenin Activation in Wilms Tumor

Keri Drake, University of Texas Southwestern

Therapeutic Targeting of FLCN-Deficient Renal Cancers

Othon Iliopoulos, Massachusetts General Hospital

Molecular Characterization and Therapeutic Targeting of TFE3 Fusion Kidney Cancers

Srinivas Viswanathan, Dana Farber Cancer Institute